ResMed Inc. (ASX: RMD) shares have hit a 52-week low, but the valuation, earnings growth, and sleep health opportunity look ...

ResMed posted stronger-than-expected Q1 2026 results with revenue of $1.43 billion and EPS of $2.86, driven by robust mask and device demand. The company announced CFO Brett Sandercock will retire in ...

ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a ...

Q3 reiterated FY 2026 gross margin range “62% to 63%” (CFO Sandercock), consistent with Q2’s updated FY 2026 gross margin range.

Resmed said its Chief Financial Officer will retire in May and announced plans to acquire a startup with an FDA de novo ...

Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales ...

ResMed Inc (RMD) reports an 11% revenue increase and strategic acquisition plans, while navigating supply chain challenges and competitive pressures.

Expanding from its core sleep apnoea franchise, Resmed has paid $500 million for a company with a treatment for the ... Read ...

The Resmed CDI (AX: RMD) share price is in focus today after the company posted third-quarter revenue up 11% to US$1.43 ...

ResMed’s first quarter saw the company deliver revenue and earnings above Wall Street expectations, yet the market responded ...

RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools ...

Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...